Nomogram for Overall Survival of Patients With Progressive Metastatic Prostate Cancer After Castration

Smaletz, Òren; Scher, Howard I.; Small, Eric J.; Verbel, David; McMillan, Alex; Regan, Kevin; Kelly, William Kevin; Kattan, Michael W.

doi:10.1200/jco.2002.11.021

Cited by 364 publications

(246 citation statements)

References 40 publications

Supporting

Mentioning

224

Contrasting

Unclassified

Order By: Relevance

“…18 In large multivariate analyses of patients with metastatic androgen-independent prostate cancer, elevated levels of serum total ALP were independently associated with shorter OS. 19,20 Our current results also indicted that patients with baseline serum total ALP o110 IU l 21 had shorter OS than patients with baseline serum total ALP ,110 IU l 21 (15.0 months vs. 26.0 months, P,0.001). Baseline ALP o110 IU l 21 predicted a nearly two-fold increased risk of death (HR51.934).…”

Section: Discussionsupporting

confidence: 66%

Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy

Qu¹,

Dai²,

Kong³

et al. 2012

Asian J Androl

View full text Add to dashboard Cite

This study aims to evaluate the potential value of patient characteristics in predicting overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel-based thermotherapy. A total of 115 patients with mCRPC undergoing a docetaxel q3w regimen were enrolled in this study. A survival analysis was performed using the Kaplan-Meier method. Cox proportional hazards models were used to evaluate the prognostic value of all covariates for OS. OS was also analysed after stratifying patients according to the results of multivariate analysis. The median OS for the entire cohort was 17.0 months. The multivariate analysis showed that the prostate-specific antigen doubling time (PSADT), baseline haemoglobin (Hb) concentration, alkaline phosphatase (ALP) concentration, cycles of chemotherapy and time to castration resistance were independent prognostic factors of OS. According to the presence of PSADT ,46.3 days and baseline ALP o110 IU l 21 , all patients were divided into three risk groups: low-risk group (no risk factors), intermediate-risk group (one risk factor) and high-risk group (two risk factors). Median OSs for patients in low-, intermediate-and high-risk groups were 28.0 months (95% CI: 23.8-32.2), 21.0 months (95% CI: 18.9-23.1) and 11.0 months (95% CI: 7.6-14.4), respectively (P,0.001). In conclusion, PSADT, baseline Hb concentration, ALP concentration, cycles of chemotherapy and time to castration resistance were independent prognostic factors of OS in Chinese patients with mCRPC treated with docetaxel. PSADT combined with the baseline ALP concentration could be a useful risk stratification parameter for evaluating survival outcomes.

show abstract

Section: Discussionsupporting

confidence: 66%

Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy

Qu¹,

Dai²,

Kong³

et al. 2012

Asian J Androl

View full text Add to dashboard Cite

show abstract

“…Almost all reports were of a prognostic nomogram for CRPC patients, and there are few reports about a prognostic nomogram for hormone-naïve progressive prostate cancer before treatment [15][16][17][18].…”

Section: Discussionmentioning

confidence: 99%

Nomogram for Overall Survival of Japanese Patients with Bone Metastatic Prostate Cancer

Miyoshi¹,

Noguchi²,

Yanagisawa³

et al. 2014

Med Surg Urol

View full text Add to dashboard Cite

Objective: We analyzed the relationship between prostate cancer outcome and pretreatment clinical factors, and developed a prognostic nomogram for Overall Survival (OS) of patients with bone metastasis. Methods:Beginning in 1993 to 2011, 463 consecutive prostate cancer patients with bone metastasis were treated. Data sets from 361 patients were used to develop the nomogram (training data), and data sets of 102 patients were used for validation of the nomogram (validation data). Using the external validation data set, the nomogram was assessed for discriminatory ability, and the predictions were assessed for calibration accuracy by plotting actual survival against predicted risk.Results: Of 361 training data set, 205 (56.8%) patients died, 169 (46.8%) deaths of which were due to prostate cancer. The Median follow-up of patients were 55.2 months. In multivariate analysis, patient age, serum PSA, clinical T stage, extent of disease on bone scan (EOD), and biopsy Gleason sum were independent prognostic factors. We developed a prognostic model for prostate cancer patients with bone metastasis, consisting of these five factors. This nomogram can be used to estimate 1-, 3-, and 5-year survival probability. External validation of this model using 102 validation data sets showed reasonable accuracy (c-index 0.719), although with slight underestimation. Conclusion:Our pretreatment prognostic nomogram might be useful for Japanese prostate cancer patients with bone metastasis.

show abstract

“…The prognosis of hormone-refractory patients is dismal and the overall survival is about 13-16 months on average. 6,7 The relatively long survival of these patients, however, facilitates the onset of skeletal complications. 3 Until the disease is responsive to androgen deprivation, adverse skeletal events and metabolic disturbances are rare.…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease

Tucci

Mosca

Lamanna

et al. 2008

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Bone metabolic disruption that occurs in bone metastatic prostate cancer could lead to disturbances of calcium metabolism. The prognostic role of either hypocalcemia or hypercalcemia was assessed in a consecutive series of hormone-refractory bone metastatic prostate cancer patients. Serum calcium was measured in 192 patients. The presence of hypocalcemia and hypercalcemia was related with baseline biochemical and clinical characteristics and the role of these two calcium disturbances in predicting prognosis and adverse skeletal-related events (SREs) was assessed. As compared to normocalcemic patients, hypocalcemic patients (n ¼ 51) had higher tumor load in bone (P ¼ 0.005), higher plasma chromogranin A (CgA, P ¼ 0.01), serum alkaline phosphatase (P ¼ 0.01), urinary N-telopeptide (NTX, P ¼ 0.002) and lower hemoglobin values (P ¼ 0.01), while hypercalcemic patients (n ¼ 16) had higher plasma CgA (P ¼ 0.001) and serum lactate dehydrogenase values (P ¼ 0.001), higher bone pain (P ¼ 0.003) and a lower frequency of pure osteoblastic lesions (P ¼ 0.001). Hypercalcemia was significantly associated with poor prognosis: hazard ratio (HR), 1.9 (95% confidence Interval (CI) 1.2-3.3) and higher risk to develop SREs HR, 2.5 (95% CI 1.2-5.2, P ¼ 0.01), while hypocalcemia was not associated with poor prognosis. The prognostic role of hypercalcemia was maintained in multivariate analysis after adjusting for validated prognostic parameters: HR, 2.72 (95% CI 1.1-6.8, P ¼ 0.03). These data suggest that serum calcium levels should be taken into account in the clinical decision-making process of bone metastatic prostate cancer patients. Patients with asymptomatic hypercalcemia could benefit of a strict follow-up and an immediate bisphosphonate treatment. Further prospective clinical trials are needed to confirm this finding.

show abstract

Nomogram for Overall Survival of Patients With Progressive Metastatic Prostate Cancer After Castration

Cited by 364 publications

References 40 publications

Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy

Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy

Nomogram for Overall Survival of Japanese Patients with Bone Metastatic Prostate Cancer

Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease

Contact Info

Product

Resources

About